Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
I work with companies to confront addiction in the workplace. The hidden crisis is costing corporate America millions.- America's Confided in Fridge in 2024
- Flourishing in a Remote Workplace: Individual Techniques
- 'Here we go again': Businesses grapple with fuel costs
- A Manual for Pick Viable Psychological well-being Backing Administrations In 2024
- US FDA grants market authorization to six on! PLUS nicotine pouch products
- 'Harry Potter' fans rejoice: HBO releases 1st trailer for new TV series, set to premiere this Christmas
- New UPS distribution center in Taiwan doubles capacity, productivity
- The Best 20 Tunes that Characterized an Age
